【drug-news】人类抗AIDS疫苗实验终止
这个帖子发布于 17 年零 305 天前，其中的信息可能已发生改变或有所发展。
http://timesofindia.indiatimes.com/India/Human_trials_of_anti-AIDS_vaccine_stopped/articleshow/2399834.cms
Human trials of anti-AIDS vaccine stopped
25 Sep 2007, 0120 hrs IST,Kounteya Sinha,TNN
NEW DELHI: The world's most promising anti-AIDS vaccine candidate has failed. Instead of protecting volunteers from the deadly virus, the vaccine actually ended up infecting numerous participants during its large scale clinical trial on humans.
The vaccine also failed to reduce the amount of HIV in the blood of those who got infected, which was a second major goal of the study. US pharmaceutical giant Merck has now halted the V520 vaccine trial called STEP. The announcement came as a major blow to international hopes of developing a HIV vaccine that could stall the spread of this deadly disease.
Earlier experiments of the vaccine on animals and smaller tests on humans had showed promising results. This led Merck to start large scale human trials in US, Australia, Latin America and the Caribbean in 2004.
Over 3,000 high risk uninfected volunteers, aged between 18 and 45 years were recruited and three doses of the vaccine were injected over six months. The final result of the vaccine's efficacy was expected by the end of 2008. But initial analysis of 1,500 volunteers by the independent Data Safety Monitoring Board, monitoring the trial, concluded that the vaccine was failing hopelessly.
Of the 741 people who received at least one dose of the vaccine, 24 cases of infection were reported in 13 months. That compared with 21 infections out of 762 people who received injections of a dummy vaccine. The search to find an anti-AIDS vaccine has involved over 20 clinical trials with tests for over 30 vaccine candidates still under way.
Since HIV was first identified in 1981, 40 million people have been infected with the virus. Annually, an estimated 4 million new infections occur, of which 90% are in developing countries. Over the last 25 years, AIDS has claimed more than 25 million lives.
Merck Research Lab's president Peter Kim said: "We share in the disappointment of the research and HIV communities today."
Human trials of anti-AIDS vaccine stopped
25 Sep 2007, 0120 hrs IST,Kounteya Sinha,TNN
NEW DELHI: The world's most promising anti-AIDS vaccine candidate has failed. Instead of protecting volunteers from the deadly virus, the vaccine actually ended up infecting numerous participants during its large scale clinical trial on humans.
The vaccine also failed to reduce the amount of HIV in the blood of those who got infected, which was a second major goal of the study. US pharmaceutical giant Merck has now halted the V520 vaccine trial called STEP. The announcement came as a major blow to international hopes of developing a HIV vaccine that could stall the spread of this deadly disease.
Earlier experiments of the vaccine on animals and smaller tests on humans had showed promising results. This led Merck to start large scale human trials in US, Australia, Latin America and the Caribbean in 2004.
Over 3,000 high risk uninfected volunteers, aged between 18 and 45 years were recruited and three doses of the vaccine were injected over six months. The final result of the vaccine's efficacy was expected by the end of 2008. But initial analysis of 1,500 volunteers by the independent Data Safety Monitoring Board, monitoring the trial, concluded that the vaccine was failing hopelessly.
Of the 741 people who received at least one dose of the vaccine, 24 cases of infection were reported in 13 months. That compared with 21 infections out of 762 people who received injections of a dummy vaccine. The search to find an anti-AIDS vaccine has involved over 20 clinical trials with tests for over 30 vaccine candidates still under way.
Since HIV was first identified in 1981, 40 million people have been infected with the virus. Annually, an estimated 4 million new infections occur, of which 90% are in developing countries. Over the last 25 years, AIDS has claimed more than 25 million lives.
Merck Research Lab's president Peter Kim said: "We share in the disappointment of the research and HIV communities today."
1 收藏点赞
